Increased Transparency for Pharmacy Benefit Manager Agreements in Medicare.
This bill mandates the Medicare Payment Advisory Commission (MedPAC) to produce two reports for Congress analyzing how agreements with Pharmacy Benefit Managers (PBMs) affect Medicare prescription drug plans. The analysis will focus on the impact of these agreements on patient out-of-pocket costs and pharmacy reimbursements. These reports aim to provide data for future legislative efforts that could potentially lower citizens' drug expenses.
Key points
Requires reports analyzing how PBM agreements influence Medicare patients' out-of-pocket drug spending and average pharmacy reimbursement rates.
The first report is due by March 2026, and the second, describing changes over time, is due by March 2028.
The reports are intended to increase transparency in drug financing but must not disclose specific drug prices or identify individual PBM entities.
Expired
Citizen Poll